Progenity is a biotech company with a multi-omics approach.
We are combining genomics, epigenomics, proteomics, and metabolomics to improve the diagnosis and treatment of disease.
About UsTransforming healthcare to be more precise and personal.
Latest News
- Progenity Announces Appointment of Surbhi Sarna to its Board of Directors Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors... June 30, 2021
- Progenity Establishes Inflammatory Bowel Disease Clinical Advisory... Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease... June 17, 2021
Featured Publications
- Targeted delivery of tofacitinib citrate to the site of disease to improve... When delivered to the site of inflammation, liquid drug formulations could result in higher tissue absorption and lower drug exposure. May 20, 2021
- Development of a novel drug delivery system for targeted treatment... The DDS2 capsule enables more precise dosing and higher local concentrations at the site of disease. May 20, 2021